Human β 2 -glycoprotein I (β 2 GPI) binds to recombinant hepatitis B surface antigen (rHBsAg), but the location of the binding domain on β 2 GPI is unknown. It has been suggested that the lipid rather than the protein moiety of rHBsAg binds to β 2 GPI. Since β 2 GPI binds to anionic phospholipids (PL) through its lipid-binding region in the fifth domain of β 2 GPI, we predicted that this lipid-binding region may also be involved in binding rHBsAg. In this study, we examined rHBsAg binding to two naturally occurring mutants of β 2 GPI, Cys306Gly and Trp316Ser, or evolutionarily conserved hydrophobic amino acid sequence, Leu313-Ala314-Phe315 in the fifth domain of β 2 GPI. The two naturally occurring mutations and two mutagenized amino acids, Leu313Gly or Phe315Ser, disrupted the binding of recombinant β 2 GPI (rβ 2 GPI) to both rHBsAg and cardiolipin (CL), an anionic PL. These results suggest that rHBsAg and CL share the same region in the fifth domain of β 2 GPI. Credence to this conclusion was further provided by competitive ELISA, where CL-bound rβ 2 GPI was incubated with increasing amounts of rHBsAg. As expected, pre-incubation of rβ 2 GPI with CL precluded binding to rHBsAg, indicating that CL and rHBsAg bind to the same region on β 2 GPI. Our data provide evidence that the lipid (PL) rather than the protein moiety of rHBsAg binds to β 2 GPI and that this binding region is located in the fifth domain of β 2 GPI, which also binds to anionic PL.
Introduction
Hepatitis B virus (HBV) belongs to a DNA-containing small enveloped hepadanavirus family, which includes woodchuck hepatitis virus [1] , ground squirrel hepatitis virus [2] , duck hepatitis B virus [3] , and heron hepatitis virus [4] . These viruses infect and replicate primarily in hepatocytes in vivo and often lead to chronic infection in the cells of their respective hosts [5] . However, the mode of entry for HBV into the human hepatocytes or the HBV receptor is not well established. Several potential candidates for HBV receptor have been reported, including a 50 kDa glycoprotein known as β 2 -glycoprotein I (β 2 GPI) [6, 7] . β 2 GPI, also known as apolipoprotein H, is a plasma glycoprotein [8] , which is associated with very lowdensity lipoproteins (VLDL), high-density lipoproteins (HDL), low-density lipoprotein (LDL) and chylomicrons, and it also exists in lipid-free form in plasma [9, 10] . Furthermore, β 2 GPI shows higher binding with oxidized LDL than native LDL [11] [12] [13] . Mature β 2 GPI is a single chain polypeptide of 326 amino acids [14] [15] [16] [17] and belongs to the short consensus repeats (SCR) or complement control protein (CCP) superfamily consisting of five homologous repeats (∼ 60 amino acids each) referred to as: GP-I domains, Sushi domains, SCRs or SSP repeats. There are 22 cysteine residues in human β 2 GPI, which are conserved in bovine, rat, mouse and dog [18] [19] [20] [21] . The first four GP-I domains (∼60 amino acids each) are structurally related, while the fifth domain (84 amino acids) is the most variable and includes a cluster of lysine residues (282-287), four highly conserved hydrophobic amino acids (313-316), and three disulfide bonds instead of two as in each of the preceding four domains. Previously, we demonstrated that the β 2 GPI cDNA transfected COS-1 cells expressed and secreted full-length recombinant β 2 GPI (rβ 2 GPI) into its culture medium that exhibits normal binding to recombinant hepatitis B surface antigen (rHBsAg) [6] . We have also demonstrated that carbohydrate side chains and arginine residues of β 2 GPI have no effect on its ability to bind to rHBsAg, but this binding was disrupted by the reduction of disulfide bonds and by the chemical modification of as few as three lysine residues [7] . Since the fifth domain of β 2 GPI has a cluster of lysine residues (282-287) and three disulfide bonds, it was predicted to contain the binding site for rHBsAg.
Using either artificial mixtures of lipids [10] or pure lipids [22] it was originally suggested that ionic and hydrophobic interactions play major roles in the binding of β 2 GPI with phospholipids (PL). The binding of β 2 GPI with anionic PL triggers the production of a subset antiphospholipid antibodies (APA) in autoimmune diseases [23, 24] . Several natural mutations have been reported in the β 2 GPI gene, including Ser88Asn, Val247-Leu, Cys306Gly, and Trp316Ser [25] [26] [27] . The two mutations in the fifth domain of β 2 GPI, Cys306Gly and Trp316Ser, may be important because Cys306Gly disrupts one of the disulfide bonds and Trp316Ser disrupts the integrity of a cluster of hydrophobic amino acids at positions 313-316 (Leu-Ala-Phe-Trp), which are evolutionarily conserved in bovine, rat, mouse, dog, and human β 2 GPI [18] [19] [20] [21] . Previously, we demonstrated that the Cys306Gly and Trp316Ser mutations disrupt the binding of plasma β 2 GPI [27] and rβ 2 GPI [28] to anionic PL. By site-directed mutagenesis, we have also shown that in addition to Trp316, Leu313 and Phe315 are required for rβ 2 GPI-PL-binding [28] .
Since the binding of β 2 GPI to rHBsAg is also dependent on the integrity of disulfide bond(s) and some lysine residues whose locations are not known [6, 7] , we hypothesized that rHBsAg would bind to the same region in the fifth domain of β 2 GPI that is involved in binding anionic PL. To examine this hypothesis, we mutagenized the fifth domain of β 2 GPI and determined the effect of these mutations on its ability to bind rHBsAg compared to PL. We also performed a competition assay in an attempt to discriminate between the binding of rHBsAg and anionic PL to rβ 2 GPI. Our results show that rHBsAg and anionic PL compete for the same binding region on rβ 2 GPI.
Materials and methods

Site-directed mutagenesis
Previously described cloned β 2 GPI cDNA in eukaryotic expression vector (pRc/CMV, Invitrogen) [16] was used to create the desired mutations using the QuickChange Site-Directed Mutagenesis kit (Strategene) as described earlier [28] . Briefly, two mutagenic primers containing the desired mutation in the middle were used to PCR amplify the entire recombinant plasmid with Pfu DNA polymerase to mutate the β 2 GPI cDNA. For each mutagenesis experiments, four to eight colonies were grown in 5 ml of LB media containing ampicillin at 37°C for 16 h. The plasmid DNA was extracted by the Spin Plasmid Miniprep kit (Qiagen) and sequenced by chain-termination dideoxynucleosides methods [29] using Sequenase Version 2.0 DNA Sequencing kit (United States Biochemical) to confirm the mutation as well as the fidelity of Pfu DNA polymerase.
Transient expression of rβ2GPI
COS-1 cells were maintained as a monolayer in Dulbecco's Modified Eagle Medium (DMEM) (Gibco-BRL) supplemented with 10% fetal bovine serum (FBS) (HyClone), 2 mM glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C under 5% CO 2 . Subconfluent monolayer of the cells grown overnight in 60 mm dishes was transiently transfected with wild-type and mutant-type β 2 GPI cDNA by DEAE-dextran method as described earlier [28, 30] . After 48 h of transfection, cells were washed twice with phosphatebuffer-saline (PBS) and incubated for an additional 4-12 h in serum-free culture media to collect the secreted rβ 2 GPI.
Detection of rβ 2 GPI by capture ELISA
The rβ 2 GPl levels were detected by modified capture ELISA [6] . Briefly, 50 μl of anti-β 2 GPI monoclonal antibody (mAb) (Chemicon International, Inc.) (5-7 μg/ml in PBS) was adsorbed onto 96 well vinyl microtiter plates (Costar) by overnight incubation at 4°C with a cover to prevent evaporation. The wells were washed three times with PBS and blocked with PBS containing 1% bovine serum albumin (BSA) at 37°C for 90 min. Fifty μI of serum-free-cell-free culture media from the transfected COS-1 cells containing rβ 2 GPI was added to the mAb-coated wells in triplicate followed by polyclonal rabbit anti-β 2 GPI antiserum (Alexis Corp.) (0.5 μg/ml in PBS containing 1% BSA) and then by alkaline phosphatase-conjugated goat anti-rabbit IgG antiserum (Instar Corp.). Each reaction was incubated at 37°C for 90 min followed by addition of 100 μI of para-nitrophenyl phosphate (PNP) substrate (Chemicon International, Inc.). The wells were washed three times with PBS between each incubation for all binding assays. The color intensity was measured as optical density (OD) at 410 nm after different time intervals.
Binding of rβ 2 GPI to rHBsAg
The rβ 2 GPI captured on anti-β 2 GPI mAb-coated wells was incubated with 2.5 μg of rHBsAg (rS,L ⁎ particles were produced in Saccharomyces cerevisiae [31, 32] ) diluted in PBS containing 1% BSA at 22°C for 16 h [6] . The bound rHBsAg was then detected by goat anti-hepatitis B surface antigen (anti-HBs) antiserum (OAKO Corp.) followed by alkaline phosphatase-conjugated rabbit anti-goat IgG antiserum (Instar Corp.). Each reaction was incubated at 37°C for 90 min followed by addition of 100 μI of PNP. The wells were washed three times with PBS between each incubation for all binding assays. The color intensity was measured as optical density (OD) at 410 nm after different time intervals.
Binding of rβ 2 GPI to cardiolipin (CL)
The binding of rβ 2 GPI to CL was performed by CL-ELISA as previously described [28] . Briefly, 96 well vinyl microtiter plates (Costar) were coated with 30 μI of CL solution in ethanol (50 μg/ml) (Sigma). The plates were dried under vacuum and blocked with PBS containing 1% milk and 0.3% gelatin at 25°C for 1 h. The plates were washed three times with PBS and incubated with 50 μI of serum-free-cell-free culture media of transfected COS-1 cells containing rβ 2 GPI at 25°C for 3 h. The bound rβ 2 GPI was detected by polyclonal rabbit anti-β 2 GPI antiserum (Alexis Corp.) (0.5 μg/ml in PBS containing 1% BSA) followed by alkaline phosphatase-conjugated goat anti-rabbit IgG antiserum (Instar Corp.). Each reaction was incubated at 37°C for 90 min followed by addition of 100 μI of PNP. The color intensity was measured as optical density (OD) at 410 nm after different time intervals.
Competition assays
A competition assay was performed in which CL-coated microtiter wells were incubated with 50 μI of serum-free-cell-free culture media from transfected COS-1 cells containing rβ 2 GPI at 25°C for 3 h followed by three washings with PBS. The CL-bound rβ 2 GPI was then allowed to bind to the increasing amount of rHBsAg (rS,L ⁎ particles, 0.31 to 10 μg/well diluted in PBS containing 1% BSA) and the bound rHBsAg was detected by anti-HBs antiserum (DAKO Corp.) as described above. Control wells received no rHBsAg. The CL-bound rβ 2 GPI was detected with polyclonal rabbit anti-β 2 GPI antiserum, as described above. A control assay was also performed where rβ 2 GPI captured by anti-β 2 GPI mAbcoated microtiter wells was allowed to bind to increasing amounts of rHBsAg (rS, L ⁎ particles, 0.31 to 10 μg/well diluted in PBS containing 1% BSA) and the bound rHBsAg was detected by anti-HBs antiserum, as described above. Fig. 1 shows the secreted levels of wild-type and mutant rβ 2 GPI into the serum-free-cell-free culture media of the transfected COS-1 cells and the binding of rβ 2 GPI wild-and mutant-types to rHBsAg or CL. While the levels of wild-type and mutant rβ 2 GPI secreted into the culture media were comparable (solid bars), the binding of rβ 2 GPI mutants (Gly306, Ser316, and Gly306/Ser316) to rHBsAg was significantly reduced as compared to the wild-type rβ 2 GPI (dark bars). The isoform-specific binding of rβ 2 GPI with rHBsAg (dark bars) was similar to that observed for the CL-rβ 2 GPI binding (light bars). These results show that a single mutation either at codon 306 or 316 in the fifth domain of β 2 GPI is sufficient to disrupt the interaction of rβ 2 GPI with either rHBsAg or CL.
Results
Effect of the Cys306Gly and Trp316Ser mutations on rHBsAg binding
Effect of hydrophobic amino acids at positions 313-316 on rHBsAg binding
In addition to the naturally occurring Trp316Ser mutation, we changed the remaining three conserved hydrophobic amino acids at positions 313-315 to neutral amino acids (Leu313Gly, Fig. 2 . Effect of hydrophobic amino acids in the fifth domain of rβ 2 GPI at positions 313-316 on its ability to bind to rHBsAg and CL. Four hydrophobic amino acids at positions 313-316 were mutated to neutral amino acids (Trp316Ser, Phe315Ser, Ala314Ser and Leu313Gly) and expressed in COS-1 cells. The secreted rβ 2 GPI forms were quantitated by capture ELISA ( n ) followed by their binding to rHBsAg ( ) or CL ( ). Results are given as mean ± SD from three independent clones in triplicate (n = 9). Fig. 1 . Effect of naturally occurring missense mutations in the fifth domain of β 2 GPI (Cys306Gly and Trp316Ser) on its ability to bind to rHBsAg and CL. The rβ 2 GPI secreted into the culture medium of mock, wild-type, Gly306 mutant, Ser316 mutant and Gly306/Ser316 double mutant transfected COS-1 cells was quantitated by capture ELISA ( n ). The secreted wild-type and mutant-type rβ 2 GPI were then allowed to bind to rHBsAg ( ) or CL ( ) on microtiter plates to examine the effect of these mutations on the ability of rβ 2 GPI to bind to rHBsAg or CL. Results are given as mean ± SD from three independent clones in triplicate (n = 9).
Ala314Ser and Phe315Ser) in β 2 GPI cDNA by site-directed mutagenesis, expressed them in COS-1 cells, and examined the binding of the mutant-type rβ 2 GPI with rHBsAg or CL (Fig. 2) . While Ala314Ser had no effect on the binding of rβ 2 GPI with rHBsAg (92%; dark bars) or CL (106%; light bars), the Leu313Gly and Phe315Ser mutations significantly reduced the binding of mutant rβ 2 GPI with rHBsAg (38% and 9% of the wild-type rβ 2 GPI, respectively; dark bars) as well as with CL (25% and 13% of the wild-type rβ 2 GPI, respectively; light bars). However, the levels of rβ 2 GPI secreted into the serumfree-cell-free culture media of the wild-type and each mutant β 2 GPI cDNA transfected COS-1 cells were comparable (solid bars). The results from these experiments further demonstrate that rHBsAg and CL share the same binding region on the β 2 GPI molecules.
Competition between rHBsAg and CL for binding to β 2 GPI
To confirm our findings that rHBsAg and CL bind to the same region on β 2 GPI, we performed two competition assays. In the first assay, CL-bound rβ 2 GPI on microtiter wells was allowed to bind with an increasing amount of rHBsAg (0.31 to 10 μg/well) (Fig. 3A) . As expected, CL-bound rβ 2 GPI exhibited no binding with rHBsAg, as the binding site for rHBsAg on β 2 GPI was blocked by CL. These results suggest that the binding of rB 2 GPI to CL is saturated with higher affinity than with rHBsAg because the addition of increasing amounts of rHBsAg did not affect rβ 2 GPI-CL binding. A second assay was designed to test whether steric hindrance or steric resistance is the reason for lack of binding of rHBsAg to rβ 2 GPI-CL complex. In this experiment, rβ 2 GPI captured by anti-β 2 GPI mAb on microtiter wells was incubated with increasing amounts of rHBsAg (Fig. 3B) . The rHBsAg binding to the mAb-captured rβ 2 GPI increased with increasing amount of rHBsAg added (Fig. 3B) as opposed to CL-bound rβ 2 GPI, which demonstrated no binding to rHBsAg even at the highest concentration (Fig. 3A) . This suggests that the binding sites for rHBsAg (or CL) and mAb on β 2 GPI are different and thus steric hindrance caused by the mAb is not a factor.
Discussion
The mechanism of HBV entry and its cellular receptor on the surface of human hepatocytes are not well understood. (B) Microtiter wells coated with anti-β 2 GPI were allowed to bind to rβ 2 GPI followed by binding to increasing amount of rHBsAg. Results are given as mean ± SD from three independent experiments in triplicate (n = 9).
However, several candidate receptors have been identified that includes β 2 GPI, which was first reported by us [6, 7] and later by others [33] [34] [35] . β 2 GPI is a secretary glycoprotein that is present in plasma in association with several lipoprotein particles as well as in lipid-free form [9, 10, 22] . Since β 2 GPI is not a transmembrane protein, a typical criterion for a viral receptor, we have earlier hypothesized that β 2 GPI present on the surface of lipoprotein particles might serve as a receptor for HBV and that the lipoprotein-HBV complex enters hepatocytes during the process of lipoprotein uptakes [6] . Although the experimental data supporting this hypothesis is lacking at present, here we have addressed several critical questions regarding the interaction between β 2 GPI and HBV.
Previously, we demonstrated that the binding of β 2 GPI with rHBsAg was disrupted by reducing the intramolecular disulfide bonds of β 2 GPI [6] and chemical modification of as few as three positively charged lysine residues of β 2 GPI [7] . However, this interaction was not affected by the removal of β 2 GPI carbohydrate side chains or chemical modification of arginine, the other positively charged amino acid [7] . These results suggested that the interaction between β 2 GPI and rHBsAg was most likely due to protein-protein interaction. On the other hand, Neurath and Strick [36] have suggested that since delipidation of rHBsAg abolishes β 2 GP1-rHBsAg binding, that the lipid moiety of rHBsAg is involved in binding β 2 GPI. Subsequently, Stefas et al. [35] have demonstrated that the myristylated pre-S1 domain of HBsAg strongly interacted with β 2 GPI, which involved PL component of HBV envelope because the removal of PL component by detergent or oxidation prevented β 2 GPI-HBsAg interaction. Notwithstanding whether it is the lipid or protein moiety of rHBsAg that binds to β 2 GPI, the β 2 GPI domain that binds to rHBsAg is not known.
A robust way to localize the binding domain of β 2 GPI is to assess the role of naturally occurring or artificially created missense mutations of β 2 GPI in binding rHBsAg. We identified two naturally occurring missense mutations, Cys306Gly and Trp316Ser in the fifth domain of β 2 GPI that disrupt PL-binding to β 2 GPI [27, 28] . The Cys306Gly mutation disrupts a disulfide bond between Cys306 and Cys281, which is critical for clustering several lysine residues [15] . The Trp316Ser mutation disrupts the integrity of an evolutionarily conserved hydrophobic amino acid sequence at positions 313-316 [15] . We hypothesized that these mutations would also disrupt β 2 GPIrHBsAg binding. Indeed our data demonstrate that the mutant rβ 2 GPI carrying one or both mutations does not bind to rHBsAg. These results show that rHBsAg and anionic PL share the same binding region on the β 2 GPI molecule. To further identify or discriminate between the binding sites of rHBsAg and anionic PL on β 2 GPI, we examined the effect of the remaining evolutionarily conserved hydrophobic amino acids in the vicinity of the Trp316Ser mutation at positions 313-315 on the ability of β 2 GPI to bind rHBsAg. Three hydrophobic amino acids at positions 313-315 were mutated to neutral residues (Leu313Gly, Ala314Ser and Phe315Ser) and the mutant rβ 2 GPI was then allowed to bind rHBsAg or CL. The Leu313Gly and Phe315Ser mutations significantly reduced the binding of mutant rβ 2 GPI to both rHBsAg and CL, while the Ala314Ser mutation showed normal binding with both rHBsAg and CL. These results indicate that the binding of β 2 GPI to rHBsAg or CL involves both ionic (shown by the Cys306Gly mutation, which disrupts the clustering of lysine residues of the fifth domain) and hydrophobic (shown by the mutagenized 313-316 sequence) interactions.
Further evidence that rHBsAg and CL share a binding region on β 2 GPI comes from our competition assay in which rβ 2 GPI bound to CL-coated microtiter wells was allowed to bind to increasing amounts of rHBsAg. If CL and rHBsAg share the same binding region on rβ 2 GPI then CL-bound rβ 2 GPI would not be able to bind rHBsAg. Indeed, we found that rβ 2 GPI bound to CL was unable to bind rHBsAg. This suggests that rHBsAg and CL compete for the same binding region on rβ 2 GPI. Although it is possible that the rβ 2 GPI bound to the well via CL might be in the correct orientation to bind to rHBsAg if the two binding regions on rβ 2 GPI were different as in case of anti-β 2 GPI antibodies (the mAb) which did bind to CL-bound rβ 2 GPI.
Our results on rHBsAg binding with β 2 GPI using the naturally occurring mutations as well as artificially created mutations in the lipid-binding region of β 2 GPI suggest that the lipid (PL) rather than the protein moiety of rHBsAg binds to rβ 2 GPI, as originally suggested by Neurath and Strick [36] and later by Stefas et al. [35] . The Cys306Gly mutation in the fifth domain of β 2 GPI disrupts the clustering of lysine residues, which are required for ionic binding with PL. Likewise, the fifth domain is necessary for the hydrophobic binding with PL [37] [38] [39] . Since mutations at this region also disrupt the binding of β 2 GPI with rHBsAg, it appears that the lipid moiety, perhaps anionic PL, rather than the protein moiety of rHBsAg, is involved in binding with β 2 GPI. Indirect support to the hypothesis that the lipid moiety of rHBsAg binds to the lipid-binding region in the fifth domain of β 2 GPI comes from another competition assay where the rβ 2 GPI captured by anti-β 2 GPI mAb on coated microtiter wells was able to bind to rHBsAg. This indicates that while the lipid moiety of rHBsAg binds to the lipid-binding region in the fifth domain of β 2 GPI, the commercially available anti-β 2 GPI mAb binds to a different domain of β 2 GPI but the rβ 2 GPI-CL complex could not bind rHBsAg confirming that the CL and rHBsAg bind to the same region on rβ 2 GPI.
In summary, we have identified the binding region for rHBsAg on β 2 GPI, which is located in the fifth domain of β 2 GPI and it appears to be the same as PL-binding region on β 2 GPI. Our results in conjunction with the observation of Neurath and Strick [36] and Stefas et al. [35] indicate that rHBsAg binds to β 2 GPI through its lipid moiety. These results also confirm our previous reports that the interaction between rHBsAg and β 2 GPI is strong and saturable [6, 7] .
